APA (7th ed.) Citation

Kereiakes, D. J., Lincoff, A., Anderson, K. M., Achenbach, R., Patel, K., Barnathan, E., . . . investigators, E. (2002). abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. American Journal of Cardiology, 90(6), 628. https://doi.org/10.1016/S0002-9149(02)02568-7

Chicago Style (17th ed.) Citation

Kereiakes, Dean J., et al. "Abciximab Survival Advantage Following Percutaneous Coronary Intervention Is Predicted by Clinical Risk Profile." American Journal of Cardiology 90, no. 6 (2002): 628. https://doi.org/10.1016/S0002-9149(02)02568-7.

MLA (9th ed.) Citation

Kereiakes, Dean J., et al. "Abciximab Survival Advantage Following Percutaneous Coronary Intervention Is Predicted by Clinical Risk Profile." American Journal of Cardiology, vol. 90, no. 6, 2002, p. 628, https://doi.org/10.1016/S0002-9149(02)02568-7.